Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.45 USD
Change Today +0.035 / 8.43%
Volume 914.7K
VICL On Other Exchanges
As of 4:30 PM 11/24/15 All times are local (Market data is delayed by at least 15 minutes).

vical inc (VICL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/15 - $1.55
52 Week Low
10/27/15 - $0.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VICAL INC (VICL)

vical inc (VICL) Related Bloomberg News

View More Bloomberg News

vical inc (VICL) Related Businessweek News

No Related Businessweek News Found

vical inc (VICL) Details

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.

68 Employees
Last Reported Date: 02/26/15
Founded in 1987

vical inc (VICL) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $821.0K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $292.2K
Vice President of Vaccine Research
Total Annual Compensation: $337.8K
Compensation as of Fiscal Year 2014.

vical inc (VICL) Key Developments

Vical Incorporated Presents at Stifel Healthcare Conference 2015, Nov-18-2015 08:00 AM

Vical Incorporated Presents at Stifel Healthcare Conference 2015, Nov-18-2015 08:00 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Andrew Hopkins, Director of Corporate Development & Project Management.

Vical Incorporated Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Revises Cash Burn Guidance the Full Year 2015

Vical Incorporated reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported total revenues of $5,017,000 against $3,442,000 a year ago. Loss from operations was $333,000 against $4,396,000 a year ago. Net loss was $300,000 against $4,364,000 a year ago. For the nine months, the company reported total revenues of $14,137,000 against $10,394,000 a year ago. Loss from operations was $6,982,000 against $11,944,000 a year ago. Net loss was $6,883,000 against $11,859,000 a year ago. Basic and diluted net loss per share was $0.08 against $0.13 a year ago. The company is updating its full year 2015 cash burn guidance to a range of between $7 million and $9 million, a reduction in cash burn from its previous forecast of between $9 million and $12 million.

Vical Incorporated to Report Q3, 2015 Results on Oct 29, 2015

Vical Incorporated announced that they will report Q3, 2015 results at 9:00 AM, Eastern Standard Time on Oct 29, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VICL:US $0.45 USD +0.035

VICL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eurocine Vaccines AB kr1.60 SEK +0.04
GenVec Inc $1.72 USD -0.07
Peregrine Pharmaceuticals Inc $1.22 USD +0.07
Transgene SA €2.57 EUR -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation VICL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at